-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Curative Therapies in Sickle Cell Disease: Which Patient, What Modality, and When to Refer

Program: Spotlight Sessions
Session: Curative Therapies for Sickle Cell Disease: Option for Some but Not Quite All
Hematology Disease Topics & Pathways:
Research, Clinical trials, Sickle Cell Disease, Clinical Practice (Health Services and Quality), Clinical Research, Education, Hemoglobinopathies, Diseases, Treatment Considerations
Sunday, December 8, 2024, 4:30 PM-5:45 PM

Santosh L. Saraf, MD

University of Illinois Chicago, Chicago, IL

Disclosures: Saraf: BEAM Therapeutics: Consultancy; Forma/Novo Nordisk: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; GBT/Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Chiesi: Consultancy; Fulcrum: Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Research Funding.

See more of: Curative Therapies for Sickle Cell Disease: Option for Some but Not Quite All
See more of: Spotlight Sessions
Previous Presentation | Next Presentation >>